Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer

Launched by ASTRAZENECA · Jul 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new tool that uses artificial intelligence (AI) to help predict the genetic risk of developing breast cancer. The tool, created by a company called WeConecta, collects information about a patient’s family history of cancer through WhatsApp messages. By looking at this family history, the AI aims to identify women who may have a higher chance of developing breast cancer due to their genes.

Women who might be eligible for this study are those aged 18 or older, who have already been identified by breast specialists as having a high genetic risk for breast cancer and have been referred to a genetic doctor for further testing. Participants will be asked to share their family’s cancer history through WhatsApp, and their medical records will be reviewed. It’s important that participants know their family history and agree to take part in the study. This study is still preparing to begin and will look back at the records of women treated between 2017 and 2024 to see how well the AI tool works.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • female patients,
• • aged 18 years or older,
• • identified as high genetic risk by breast surgeons,
• • referred to a geneticist, and
• • who agree to participate in the study.
• Exclusion Criteria:
• • male patients,
• • absence of complete information in the medical records,
• • patients unaware of their biological family history, and
• • patients who do not agree to participate in the study.